Compare Freeport-McMoRan Inc (FCX) vs Tenet Healthcare Corporation (THC) Price & Performance

Freeport-McMoRan (FCX) trades at $71.87, down 0.97% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected shortly. FCX maintains solid profitability with 11.38% net margin and 15.37% ROE, supported by robust operational cash flow of $5.61 billion in 2025. Recent news highlights copper's strategic importance for AI infrastructure, positioning FCX to benefit from long-term demand trends.

FCX presents a compelling opportunity with analyst consensus at Buy (61%) and $73.27 price target, offering 2% upside. The company's expansion projects and copper's AI-driven demand create growth potential, though rising production costs and ongoing legal investigation pose risks. Institutional sentiment remains positive given FCX's market leadership and favorable commodity outlook.

Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.

THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.